Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience

OBJECTIVE: In the treatment of advanced and recurrent colorectal cancer (ARCC), FOLFOXIRI regimens have been proven to be significantly superior to FOLFIRI in terms of the progression-free survival (PFS), response rate (RR), and overall survival (OS). Furthermore, the Tribe trial showed that the RR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Kazuma, Yamaguchi, Shun, Ito, Shinichiro, Torashima, Yasuhiro, Inoue, Yusuke, Okada, Satomi, Enjoji, Takahiro, Tetsuo, Hanako, Kuba, Sayaka, Kosaka, Taiichiro, Adachi, Tomohiko, Hidaka, Masaaki, Yamanouchi, Kosho, Kanetaka, Kengo, Takatsuki, Mitsuhisa, Eguchi, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303458/
https://www.ncbi.nlm.nih.gov/pubmed/32074573
http://dx.doi.org/10.2169/internalmedicine.3274-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303458/
https://www.ncbi.nlm.nih.gov/pubmed/32074573
http://dx.doi.org/10.2169/internalmedicine.3274-19

Ejemplares similares